OBJECTIVE: To estimate the incidence rate and predictors of seizures in patients with mild to moderate Alzheimer disease (AD). DESIGN: Cohort study of patients with mild to moderate AD in clinical trials. Risk factors for potential seizures were evaluated by stratified descriptive statistics and univariable and multivariable Cox proportional hazards regressions. SETTING: Pooled patient-level data from 10 Alzheimer Disease Cooperative Study clinical trials in mild to moderate AD from 1995 to 2010. PATIENTS: Three thousand seventy-eight subjects randomized to the treatment or placebo arms of 10 AD clinical trials. Screening Mini-Mental State Examination scores ranged between 10 and 28. RESULTS: Eighteen seizures were reported in 3078 randomized subjects, with an incidence rate of 484 per 100 000 person-years (95% CI, 287-764). Statistically significant independent risk factors for seizure were younger age (adjusted hazard ratio, 0.80; 95% CI, 0.69-0.93 per every 5 years of age), greater cognitive impairment at baseline (adjusted hazard ratio, 2.79; 95% CI, 1.06-7.33 for Mini-Mental State Examination scores <18 compared with Mini-Mental State Examination scores ≥18), and antipsychotic use at baseline (adjusted hazard ratio, 3.47; 95% CI, 1.33-9.08). CONCLUSIONS: Seizure rates in patients with mild to moderate AD in clinical trials are similar to rates observed in longer observational cohort studies, but they are greater than expected in the general elderly population. Younger age, greater degree of cognitive impairment, and history of antipsychotic use were independent risk factors for new-onset seizures in AD.
OBJECTIVE: To estimate the incidence rate and predictors of seizures in patients with mild to moderate Alzheimer disease (AD). DESIGN: Cohort study of patients with mild to moderate AD in clinical trials. Risk factors for potential seizures were evaluated by stratified descriptive statistics and univariable and multivariable Cox proportional hazards regressions. SETTING: Pooled patient-level data from 10 Alzheimer Disease Cooperative Study clinical trials in mild to moderate AD from 1995 to 2010. PATIENTS: Three thousand seventy-eight subjects randomized to the treatment or placebo arms of 10 AD clinical trials. Screening Mini-Mental State Examination scores ranged between 10 and 28. RESULTS: Eighteen seizures were reported in 3078 randomized subjects, with an incidence rate of 484 per 100 000 person-years (95% CI, 287-764). Statistically significant independent risk factors for seizure were younger age (adjusted hazard ratio, 0.80; 95% CI, 0.69-0.93 per every 5 years of age), greater cognitive impairment at baseline (adjusted hazard ratio, 2.79; 95% CI, 1.06-7.33 for Mini-Mental State Examination scores <18 compared with Mini-Mental State Examination scores ≥18), and antipsychotic use at baseline (adjusted hazard ratio, 3.47; 95% CI, 1.33-9.08). CONCLUSIONS:Seizure rates in patients with mild to moderate AD in clinical trials are similar to rates observed in longer observational cohort studies, but they are greater than expected in the general elderly population. Younger age, greater degree of cognitive impairment, and history of antipsychotic use were independent risk factors for new-onset seizures in AD.
Authors: R A Mulnard; C W Cotman; C Kawas; C H van Dyck; M Sano; R Doody; E Koss; E Pfeiffer; S Jin; A Gamst; M Grundman; R Thomas; L J Thal Journal: JAMA Date: 2000-02-23 Impact factor: 56.272
Authors: Paul S Aisen; Kimberly A Schafer; Michael Grundman; Eric Pfeiffer; Mary Sano; Kenneth L Davis; Martin R Farlow; Shelia Jin; Ronald G Thomas; Leon J Thal Journal: JAMA Date: 2003-06-04 Impact factor: 56.272
Authors: Keith A Vossel; Alexander J Beagle; Gil D Rabinovici; Huidy Shu; Suzee E Lee; Georges Naasan; Manu Hegde; Susannah B Cornes; Maya L Henry; Alexandra B Nelson; William W Seeley; Michael D Geschwind; Maria L Gorno-Tempini; Tina Shih; Heidi E Kirsch; Paul A Garcia; Bruce L Miller; Lennart Mucke Journal: JAMA Neurol Date: 2013-09-01 Impact factor: 18.302
Authors: Ping Zheng; Sandy R Shultz; Chris M Hovens; Dennis Velakoulis; Nigel C Jones; Terence J O'Brien Journal: Mol Neurobiol Date: 2013-12-10 Impact factor: 5.590
Authors: Emily L Johnson; Gregory L Krauss; Alexandra K Lee; Andrea L C Schneider; Anna M Kucharska-Newton; Juebin Huang; Clifford R Jack; Rebecca F Gottesman Journal: Neurology Date: 2019-01-25 Impact factor: 9.910
Authors: Frances K Wiseman; Tamara Al-Janabi; John Hardy; Annette Karmiloff-Smith; Dean Nizetic; Victor L J Tybulewicz; Elizabeth M C Fisher; André Strydom Journal: Nat Rev Neurosci Date: 2015-08-05 Impact factor: 34.870